The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in nonsmall-cell lung cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 352, Issue 1, 2015, Pages 129-138

  Wang, Beibei ^a   Yu, Weiwei ^a   Guo, Jiawei ^a   Jiang, Xingwu ^a   Lu, Weiqiang ^a   Liu, Mingyao ^a,b   Pang, Xiufeng ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY TARTRATE; CISPLATIN; FOCAL ADHESION KINASE; MATRIGEL; PROTEIN TYROSINE KINASE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTIPARASITIC AGENT; PROTEIN KINASE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOLOGICAL PARAMETERS; PHARMACOLOGICAL BLOCKING; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR WEIGHT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CHEMOTAXIS; DRUG EFFECTS; DRUG INTERACTION; DRUG SCREENING; HUMAN; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIMONY POTASSIUM TARTRATE; ANTIPARASITIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTAXIS; CISPLATIN; DRUG INTERACTIONS; ENZYME ACTIVATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LUNG NEOPLASMS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919705106     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.218644     Document Type: Article

References (48)

1. Algire GH, Legallais FY, and Anderson BF (1954) Vascular reactions of normal and malignant tissues in Vivo. VI. The role of hypotension in the action of components of podophyllin on transplanted sarcomas. J Natl Cancer Inst 14:879-893.
2. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, and Isner JM (1995) Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92 (Suppl)II365-II371.
3. Chong CR and Sullivan DJ, Jr (2007) New uses for old drugs. Nature 448:645-646.
4. Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ, Jr, and Liu JO (2007) Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol 2:263-270.
5. Cook KM and Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60:222-243.
6. D'Amato RJ, Loughnan MS, Flynn E, and Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082-4085.
7. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22.
8. Ferrara N, Hillan KJ, Gerber HP, and Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400.
9. Ferrara N and Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974.
10. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186.
11. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, and Anthuber M, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8:128-135.
12. Gupta SC, Sung B, Prasad S, Webb LJ, and Aggarwal BB (2013) Cancer drug discovery by repurposing: teaching new tricks to old dogs. Trends Pharmacol Sci 34:508-517.
13. Hanahan D and Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
14. Jeltsch M, Leppänen VM, Saharinen P, and Alitalo K (2013) Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harb Perspect Biol 5:a009183.
15. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, and Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418-1423.
16. Kanda S, Miyata Y, Kanetake H, and Smithgall TE (2007) Non-receptor proteintyrosine kinases as molecular targets for antiangiogenic therapy (Review). Int J Mol Med 20:113-121.
17. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049.
18. Kim LC, Song L, and Haura EB (2009) Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 6:587-595.
19. Lamalice L, Le Boeuf F, and Huot J (2007) Endothelial cell migration during angiogenesis. Circ Res 100:782-794.
20. Lecureur V, Lagadic-Gossmann D, and Fardel O (2002a) Potassium antimonyl tartrate induces reactive oxygen species-related apoptosis in human myeloid leukemic HL60 cells. Int J Oncol 20:1071-1076.
21. Lecureur V, Le Thiec A, Le Meur A, Amiot L, Drenou B, Bernard M, Lamy T, Fauchet R, and Fardel O (2002b) Potassium antimonyl tartrate induces caspase- and reactive oxygen species-dependent apoptosis in lymphoid tumoral cells. Br J Haematol 119:608-615.
22. Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ, Kim JH, Kim KW, and Kwon YG (1999) Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 264:743-750.
23. Lemmon MA and Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117-1134.
24. Liu P, Cheng H, Roberts TM, and Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644.
25. Lund EL, Spang-Thomsen M, Skovgaard-Poulsen H, and Kristjansen PE (1998) Tumor angiogenesis - a new therapeutic target in gliomas. Acta Neurol Scand 97:52-62.
26. Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, and Wistuba II (2007) KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 13:2890-2896.
27. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, and Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5:505-515.
28. Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, and Pisacane A, et al. (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18:2515-2525.
29. Montesano R, Orci L, and Vassalli P (1983) In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices. J Cell Biol 97:1648-1652.
30. Nacev BA, Grassi P, Dell A, Haslam SM, and Liu JO (2011) The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells. J Biol Chem 286:44045-44056.
31. Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, and Hirohashi S (2000) Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer Res 6:2431-2439.
32. Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, Fujise K, and Liu M (2009a) Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways. Cancer Res 69 :518-525.
33. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, and Liu M (2009b) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69:5893-5900.
34. Parman T, Wiley MJ, and Wells PG (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 5:582-585.
35. Paz-Ares LG, Biesma B, Heigener D, von Pawel J, Eisen T, Bennouna J, Zhang L, Liao M, Sun Y, and Gans S, et al.; NSCLC [non-small-cell lung cancer] Research Experience Utilizing Sorafenib (NExUS) Investigators Study Group (2012) Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 30:3084-3092.
36. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, and Rusnati M (2005) Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16:159-178.
37. Pyun BJ, Choi S, Lee Y, Kim TW, Min JK, Kim Y, Kim BD, Kim JH, Kim TY, and Kim YM, et al. (2008) Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity. Cancer Res 68:227-235.
38. Qian Y, Liu S, Guan Y, Pan H, Guan X, Qiu Z, Li L, Gao N, Zhao Y, and Li X, et al. (2013) Lgr4-mediated Wnt/b-catenin signaling in peritubular myoid cells is essential for spermatogenesis. Development 140:1751-1761.
39. Ranpura V, Hapani S, and Wu S (2011) Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305:487-494.
40. Saharinen P, Eklund L, Pulkki K, Bono P, and Alitalo K (2011) VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 17:347-362.
41. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550.
42. Schulert AR, Rassoul AA, Mansour M, Girgis N, McConnell E, and Farid Z (1966) Biological disposition of antibilharzial antimony drugs. II. Antimony fate and uptake by Schistosoma haematobium eggs in man. Exp Parasitol 18:397-402.
43. Sennino B and McDonald DM (2012) Controlling escape from angiogenesis inhibitors. Nat Rev Cancer 12:699-709.
44. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, and Fedewa S, et al. (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241.
45. Siegel R, Naishadham D, and Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
46. Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi S, Kotake Y, and Konishi Y (1999) Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 5:2506-2510.
47. Wozniak A (2012) Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Crit Rev Oncol Hematol 82:200-212.
48. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW, Xiong Y, Tseng LM, Li SH, and Ding Z, et al. (2011) Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17:461-469.